Welcome to our dedicated page for Savara SEC filings (Ticker: SVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Savara Inc. (SVRA) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases, and its filings offer detailed insight into the development and financing of its lead program, MOLBREEVI, for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).
Through this page, readers can review current and historical reports such as Forms 8-K, which describe material events including public offerings of common stock and pre-funded warrants, royalty funding agreements tied to potential future U.S. net sales of MOLBREEVI, and updates to corporate presentations. Filings also confirm that Savara’s common stock trades on The Nasdaq Global Select Market under the symbol SVRA and describe the company’s status as a clinical stage biopharmaceutical company focused on rare respiratory diseases.
Key documents for investors include periodic reports like annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain information on research and development expenses, general and administrative costs, and other financial data related to the MOLBREEVI program and corporate operations. Current reports on Form 8-K highlight transactions such as underwritten public offerings, the entry into material definitive agreements, and royalty funding arrangements.
Stock Titan enhances these filings with AI-powered summaries that help explain the significance of complex disclosures, including capital-raising transactions, royalty structures, and covenants described in agreements. Users can quickly understand how specific filings relate to Savara’s rare respiratory disease focus, its Phase 3 development of MOLBREEVI, and its preparation for potential commercialization, while still having direct access to the full text of each SEC document.
Savara Inc. reported widening losses as it advances its sole product candidate, MOLBREEVI, an inhaled GM-CSF for autoimmune pulmonary alveolar proteinosis. Net loss was $30.4 million for the quarter and $57.0 million for the six months, up from $22.2 million and $42.6 million a year earlier, driven by higher research-and-development and commercial-preparation costs.
The company holds $17.4 million in cash and $129.0 million in short-term investments (total ~$146.4 million) and states this is sufficient to fund operations for at least the next 12 months. Savara received an FDA Refusal to File for its BLA but says the RTF raised CMC information requests only, not safety or efficacy; the company plans a December resubmission and will request Priority Review. Savara has a $200 million Hercules term loan facility with an initial $30 million draw, conditional future tranches tied to regulatory and revenue milestones and covenanted cash requirements that could restrict liquidity.
Schedule 13G filing for Savara Inc. (SVRA) shows that a group of Venrock Healthcare Capital Partners funds and related managers/individuals has crossed the 5% disclosure threshold.
- Reporting group: Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, and principals Nimish Shah and Bong Y. Koh.
- Aggregate beneficial ownership: 9,021,507 common shares.
- Ownership breakdown: 1,997,410 shares (VHCP III); 199,772 shares (VHCP Co-Investment III); 6,824,325 shares (VHCP EG).
- Percentage of class: 5.2% of Savara’s 172,836,922 outstanding shares (as of 13 May 2025).
- Voting & dispositive power: 0 shares sole; 9,021,507 shares shared—indicating coordinated but passive ownership. Filing is under Rule 13d-1(c), not 13D, so the group states no intent to influence control.
- Date of event triggering filing: 30 June 2025; filing signed 08 July 2025.
The disclosure signals that Venrock, a life-science–focused investor, holds a meaningful but non-controlling position in Savara. Investors often view recognized sector specialists taking a >5% stake as a vote of confidence, yet the filing itself does not imply any change in Savara’s strategy, capital structure, or governance. The stake is passive and therefore has limited immediate operational impact.